A Panel of Urinary Biomarkers to Monitor Reversibility of Renal Injury and a Serum Marker with Improved Potential to Assess Renal Function
October 5, 2010 Renal Biomarker Qualification Submission: A Dialog Between the FDA-EMEA and Predictive Safety Testing Consortium
October 5, 2010 Urinary Clusterin, Cystatin C, [beta]2-Microglobulin and Total Protein as Markers to Detect Drug-Induced Kidney Injury
Critical Path Institute President/CEO Receives Award of Excellence Raymond L. Woosley, MD, PhD, President/CEO of Tucson-based Critical Path Institute (CPI), was recently presented with the prestigi
Global Partners Join Forces to Speed Development of New TB Drug Combinations FDA applauds effort to take years off development of much needed TB treatments
